The Autocrine FGF/FGFR System in both Skin and Uveal Melanoma: FGF Trapping as a Possible Therapeutic Approach.
FGF
FGF receptors
liver metastasis
tumor grafts
uveal melanoma
zebrafish
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
04 Sep 2019
04 Sep 2019
Historique:
received:
02
08
2019
revised:
29
08
2019
accepted:
29
08
2019
entrez:
7
9
2019
pubmed:
7
9
2019
medline:
7
9
2019
Statut:
epublish
Résumé
Fibroblast growth factors (FGFs) play non-redundant autocrine/paracrine functions in various human cancers. The Cancer Genome Atlas (TCGA) data mining indicates that high levels of FGF and/or FGF receptor (FGFR) expression are associated with reduced overall survival, chromosome 3 monosomy and
Identifiants
pubmed: 31487962
pii: cancers11091305
doi: 10.3390/cancers11091305
pmc: PMC6770058
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Associazione Italiana per la Ricerca sul Cancro
ID : IG grant n° 18943
Organisme : Associazione Italiana per la Ricerca sul Cancro
ID : MFAG grant n° 18459
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Clin Ophthalmol. 2016 Oct 25;10:2113-2119
pubmed: 27822007
Curr Eye Res. 2006 Sep;31(9):775-85
pubmed: 16966150
PLoS One. 2012;7(4):e35826
pubmed: 22558232
Diabetologia. 2017 Apr;60(4):719-728
pubmed: 28083635
Melanoma Res. 2007 Dec;17(6):380-6
pubmed: 17992121
Biochim Biophys Acta. 2013 Sep;1832(9):1371-7
pubmed: 23357577
Hematol Oncol Clin North Am. 2012 Dec;26(6):1169-84
pubmed: 23116575
Invest Ophthalmol Vis Sci. 2011 May 11;52(6):3094-102
pubmed: 21330669
Biochim Biophys Acta. 2015 May;1852(5):839-50
pubmed: 25558817
J Cell Biochem. 2001;81(3):477-87
pubmed: 11255230
Ther Adv Med Oncol. 2018 Feb 21;10:1758834018757175
pubmed: 29497459
J Med Chem. 2016 May 26;59(10):4651-63
pubmed: 27138345
J Pathol Clin Res. 2017 Nov 13;4(1):26-38
pubmed: 29416875
Cancer Cell. 2017 Aug 14;32(2):204-220.e15
pubmed: 28810145
Oncotarget. 2016 Jan 19;7(3):2936-50
pubmed: 26655090
Lancet Oncol. 2018 Jan;19(1):e16
pubmed: 29233557
Int J Cancer. 1997 Nov 14;73(4):470-8
pubmed: 9389558
Biochim Biophys Acta Rev Cancer. 2018 Jan;1869(1):53-63
pubmed: 29175552
Expert Rev Anticancer Ther. 2018 Sep;18(9):861-872
pubmed: 29936878
Mol Cancer Ther. 2013 Dec;12(12):2760-71
pubmed: 24130051
Annu Rev Immunol. 2005;23:337-66
pubmed: 15771574
J Biol Chem. 2006 Aug 11;281(32):22605-13
pubmed: 16769728
Curr Eye Res. 1999 Feb;18(2):125-9
pubmed: 10223656
Melanoma Res. 2008 Jun;18(3):191-200
pubmed: 18477893
BMC Cancer. 2019 May 22;19(1):484
pubmed: 31117965
Pharmacol Ther. 2017 Nov;179:171-187
pubmed: 28564583
Biomed Res Int. 2016;2016:4521807
pubmed: 27366747
Onco Targets Ther. 2017 Nov 08;10:5317-5328
pubmed: 29184418
Front Endocrinol (Lausanne). 2019 Jan 08;9:775
pubmed: 30671022
Curr Cancer Drug Targets. 2018;18(10):988-998
pubmed: 29692251
Bull Cancer. 2018 Oct;105(10):967-980
pubmed: 30217336
Pharmacol Res. 2016 May;107:172-185
pubmed: 27013279
Cancer Cell. 2015 Aug 10;28(2):225-39
pubmed: 26267536
Clin Exp Metastasis. 1997 Sep;15(5):509-18
pubmed: 9247253
EMBO Mol Med. 2019 Feb;11(2):
pubmed: 30610113
Br J Ophthalmol. 2002 Apr;86(4):440-7
pubmed: 11914215
J Cell Sci. 1999 Mar;112 ( Pt 5):623-30
pubmed: 9973597
Invest Ophthalmol Vis Sci. 2009 Mar;50(3):1047-57
pubmed: 19029025
Int J Cancer. 1995 Jul 17;62(2):155-61
pubmed: 7622289
Appl Clin Genet. 2016 Sep 06;9:147-55
pubmed: 27660484
Cancer Cell. 2013 Apr 15;23(4):477-88
pubmed: 23597562
Int J Clin Exp Pathol. 2013 Jun 15;6(7):1230-44
pubmed: 23826405
Nat Genet. 2019 Jul;51(7):1123-1130
pubmed: 31253977
J Pathol. 2013 Jun;230(2):228-38
pubmed: 23424081
Front Oncol. 2018 Nov 01;8:472
pubmed: 30443492
Trans Am Ophthalmol Soc. 2016 Aug;114:T5
pubmed: 28018010
Mol Cancer Ther. 2011 Sep;10(9):1600-10
pubmed: 21764903
Cancers (Basel). 2019 Jul 20;11(7):null
pubmed: 31330784